Study of OLP-1002 Injections for Reducing Moderate to Severe Pain Due to Osteoarthritis in Hip and/or Knee Joint
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- OliPass Corporation
- Target Recruit Count
- 134
- Registration Number
- NCT05216341
- Locations
- 🇦🇺
Emeritus Research, Melbourne, Victoria, Australia
🇦🇺Northern Beaches Clinical Research, Brookvale, New South Wales, Australia
🇦🇺Novatrials, Kotara, New South Wales, Australia
OLP-1002 is Being Studied in the Treatment of Pain.
Early Phase 1
Completed
- Conditions
- Pain
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- OliPass Corporation
- Target Recruit Count
- 116
- Registration Number
- NCT03760913
- Locations
- 🇬🇧
Leeds CRU, Leeds, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath